

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/9/2001.

<b>Name of entity</b> : Neuren Pharmaceuticals Limited
<b>ABN</b> : 111 496 130

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Dr Robin Lance Congreve
<b>Date of last notice</b>	11 February 2008

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect interests
<b>Nature of indirect interest (including registered holder)</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	1. T.A.C. Murray and Quartet Equities Limited as trustees of The Congreve Family Trust and the relevant interest is as a beneficiary of The Congreve Family Trust  2. EndocrinZ Founders Limited and the relevant interest is as a director and shareholder  3. Oceania & Eastern Biotech Limited and the relevant interest is as a director and indirect shareholding held by associated interests  4. Hazardous Investments Limited and the relevant interest is as a director and indirect shareholding held by associated interests
<b>Date of change</b>	30 September 2008
<b>No. of securities held prior to change</b>	17,928,907 Ordinary Shares and 1,528,892 unlisted options to acquire Ordinary Shares at NZ\$0.392 each until March 2009
<b>Class</b>	Ordinary Shares
<b>Number acquired</b>	4,457,317 Ordinary Shares by Oceania & Eastern Biotech Limited

---

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

---

<b>Number disposed</b>	Nil
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	A\$0.08 per Ordinary Share
<b>No. of securities held after change</b>	22,386,224 Ordinary Shares and 1,528,892 unlisted options to acquire Ordinary Shares at NZ\$0.392 each until March 2009
<b>Nature of change</b> <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	Sub-underwrite of Share Purchase Plan by Oceania & Eastern Biotech Limited

**Part 2 – Change of director's interests in contracts**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	NIL
<b>Nature of interest</b>	
<b>Name of registered holder (if issued securities)</b>	
<b>Date of change</b>	
<b>No. and class of securities to which interest related prior to change</b> <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	
<b>Interest acquired</b>	
<b>Interest disposed</b>	
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	
<b>Interest after change</b>	

---

+ See chapter 19 for defined terms.